In a recently completed phase II clinical trial [8], we treated 30 AML patients with autologous, WT1 mRNA-electroporated moDCs following standard induction chemotherapy; 27 of them were in CR and three were in PR. This evidence concerns the gene WT1 and acute myeloid leukemia.